Questions remain following first COVID-19 vaccine results

Neutralizing antibodies are the benchmark for testing SARS-CoV-2 vaccines. Brain light / Alamy Stock Photo
Access options
Subscribe to Journal
Get full journal access for 1 year
$259.00
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.